Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Epithelial-to mesenchymal transition
Epithelioid sarcoma
Growth factor receptors
HDAC inhibition
Rhabdoid tumor
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
20 Jul 2021
20 Jul 2021
Historique:
received:
18
12
2020
accepted:
10
07
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Epithelioid sarcomas and rhabdoid tumors are rare, aggressive malignancies with poor prognosis. Both are characterized by INI1 alterations and deregulation of growth factor receptors albeit their interaction has not been elucidated. In this study, we investigated the activity of a panel of epigenetic modulators and receptor tyrosine kinase inhibitors in vitro on respective cell lines as well as on primary patient-derived epithelioid sarcoma cells, and in vivo on xenografted mice. Focusing on histone deacetylase (HDAC) inhibitors, we studied the mechanism of action of this class of agents, its effect on growth factor receptor regulation, and changes in epithelial-to-mesenchymal transition by using cell- and RT-qPCR-based assays. Pan-HDAC inhibitor panobinostat exhibited potent anti-proliferative activity at low nanomolar concentrations in A204 rhabdoid tumor, and VAESBJ/GRU1 epithelioid sarcoma cell lines, strongly induced apoptosis, and resulted in significant tumor growth inhibition in VAESBJ xenografts. It differentially regulated EGFR, FGFR1 and FGFR2, leading to downregulation of EGFR in epithelioid sarcoma and to mesenchymal-to-epithelial transition whereas in rhabdoid tumor cells, EGFR was strongly upregulated and reinforced the mesenchymal phenotype. All three cell lines were rendered more susceptible towards combination with EGFF inhibitor erlotinib, further enhancing apoptosis. HDAC inhibitors exhibit significant anticancer activity due to their multifaceted actions on cytotoxicity, differentiation and drug sensitization. Our data suggest that the tailored, tissue-specific combination of HDAC inhibitors with therapeutics which target cellular salvage mechanisms might increase their therapeutic relevance.
Sections du résumé
BACKGROUND
BACKGROUND
Epithelioid sarcomas and rhabdoid tumors are rare, aggressive malignancies with poor prognosis. Both are characterized by INI1 alterations and deregulation of growth factor receptors albeit their interaction has not been elucidated.
METHODS
METHODS
In this study, we investigated the activity of a panel of epigenetic modulators and receptor tyrosine kinase inhibitors in vitro on respective cell lines as well as on primary patient-derived epithelioid sarcoma cells, and in vivo on xenografted mice. Focusing on histone deacetylase (HDAC) inhibitors, we studied the mechanism of action of this class of agents, its effect on growth factor receptor regulation, and changes in epithelial-to-mesenchymal transition by using cell- and RT-qPCR-based assays.
RESULTS
RESULTS
Pan-HDAC inhibitor panobinostat exhibited potent anti-proliferative activity at low nanomolar concentrations in A204 rhabdoid tumor, and VAESBJ/GRU1 epithelioid sarcoma cell lines, strongly induced apoptosis, and resulted in significant tumor growth inhibition in VAESBJ xenografts. It differentially regulated EGFR, FGFR1 and FGFR2, leading to downregulation of EGFR in epithelioid sarcoma and to mesenchymal-to-epithelial transition whereas in rhabdoid tumor cells, EGFR was strongly upregulated and reinforced the mesenchymal phenotype. All three cell lines were rendered more susceptible towards combination with EGFF inhibitor erlotinib, further enhancing apoptosis.
CONCLUSIONS
CONCLUSIONS
HDAC inhibitors exhibit significant anticancer activity due to their multifaceted actions on cytotoxicity, differentiation and drug sensitization. Our data suggest that the tailored, tissue-specific combination of HDAC inhibitors with therapeutics which target cellular salvage mechanisms might increase their therapeutic relevance.
Identifiants
pubmed: 34281526
doi: 10.1186/s12885-021-08579-w
pii: 10.1186/s12885-021-08579-w
pmc: PMC8290558
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
Receptors, Growth Factor
0
Panobinostat
9647FM7Y3Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
833Informations de copyright
© 2021. The Author(s).
Références
Br J Pharmacol. 2017 Oct;174(20):3608-3622
pubmed: 28749535
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):
pubmed: 27599530
BMC Cancer. 2013 Jun 13;13:286
pubmed: 23764045
JAMA Oncol. 2018 Sep 1;4(9):e180219
pubmed: 29800950
Mol Cancer. 2015 Sep 15;14:167
pubmed: 26370283
Anticancer Drugs. 2015 Mar;26(3):301-11
pubmed: 25415657
Nature. 1998 Jul 9;394(6689):203-6
pubmed: 9671307
Cancer Cell. 2012 Jul 10;22(1):9-20
pubmed: 22789535
Clin Orthop Relat Res. 2009 Nov;467(11):2939-48
pubmed: 19224301
Clin Cancer Res. 2011 Sep 15;17(18):5901-12
pubmed: 21821699
PLoS One. 2011 Mar 25;6(3):e18087
pubmed: 21464950
Cell Rep. 2017 Nov 14;21(7):1737-1745
pubmed: 29141209
Nat Med. 2015 Jun;21(6):555-9
pubmed: 25939062
Nat Rev Genet. 2016 May;17(5):284-99
pubmed: 26972587
Am J Clin Pathol. 2009 Feb;131(2):222-7
pubmed: 19141382
Cancer Res. 2006 Jan 15;66(2):944-50
pubmed: 16424029
J Neurosurg Pediatr. 2018 Sep;22(3):288-296
pubmed: 29856296
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
pubmed: 11597399
Oncotarget. 2016 Feb 2;7(5):5440-60
pubmed: 26713601
Mod Pathol. 2013 Mar;26(3):385-92
pubmed: 23060122
Neoplasia. 2012 Aug;14(8):670-7
pubmed: 22952420
Cancer Lett. 2009 Aug 8;280(2):233-41
pubmed: 19344997
PLoS One. 2009;4(2):e4482
pubmed: 19221586
Clin Cancer Res. 2004 Sep 1;10(17):5940-8
pubmed: 15355927
Arch Pathol Lab Med. 2009 May;133(5):814-9
pubmed: 19415960
Mod Pathol. 2010 Apr;23(4):574-80
pubmed: 20118913
Expert Opin Ther Targets. 2018 Apr;22(4):365-379
pubmed: 29528755
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13796-800
pubmed: 11095756
Clin Cancer Res. 2016 Jul 15;22(14):3560-70
pubmed: 26920892
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
PLoS One. 2015 Nov 23;10(11):e0142612
pubmed: 26599335
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
Anticancer Res. 2016 Aug;36(8):3883-7
pubmed: 27466490
Clin Cancer Res. 2017 Oct 15;23(20):6101-6112
pubmed: 28733441
Cell Rep. 2016 Oct 25;17(5):1265-1275
pubmed: 27783942
Cancer Genet. 2014 Sep;207(9):365-72
pubmed: 24853101
Oncotarget. 2015 Jan 30;6(3):1750-68
pubmed: 25638155
Nat Med. 2013 Nov;19(11):1438-49
pubmed: 24202396
Int J Cancer. 2014 Dec 15;135(12):2962-71
pubmed: 24771540
Clin Cancer Res. 2013 Nov 15;19(22):6230-41
pubmed: 24081976
Nat Rev Drug Discov. 2017 Apr;16(4):241-263
pubmed: 28280262
PLoS One. 2017 Jan 4;12(1):e0169485
pubmed: 28052119
PLoS One. 2013 Oct 30;8(10):e77652
pubmed: 24204904
Oncogene. 2007 Aug 13;26(37):5541-52
pubmed: 17694093
Am J Clin Pathol. 1987 Mar;87(3):319-26
pubmed: 3548316
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
EMBO Rep. 2000 Dec;1(6):500-6
pubmed: 11263494
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Cancer Cell. 2016 Mar 14;29(3):379-393
pubmed: 26923874
Biochim Biophys Acta. 2013 Mar;1833(3):663-71
pubmed: 23246564
Mol Cancer Res. 2016 Jan;14(1):35-43
pubmed: 26396249
Mol Cancer Ther. 2007 Sep;6(9):2515-24
pubmed: 17876048